Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Prognosis of patients with ascites after PleurX insertion: an observational study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Antibiotics: a risk factor for irritable bowel syndrome in a population-based cohort

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Quality of life, performance status, and work capacity after post-endoscopic retrograde cholangiopancreatography pancreatitis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Microscopic colitis in Denmark and Sweden: incidence, putative risk factors, histological assessment and endoscopic activity

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Direct acting antiviral treatment of chronic hepatitis C in Denmark: factors associated with and barriers to treatment initiation

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Nutritional status and nutritional risk in patients with neuroendocrine tumors

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. MR-skanning til diagnostik af nonalkoholisk fedtleversygdom

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Preemptive-TIPS improves outcome in high-risk variceal bleeding: An observational study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. The role of Branched Chain Amino Acids in the treatment of hepatic Encephalopathy

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  4. Cerebral Blood Flow and Metabolism in Hepatic Encephalopathy-A Meta-Analysis

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

Vis graf over relationer

OBJECTIVE: To evaluate the safety of PleurX in cirrhotic patients with refractory ascites.

METHODS: We prospectively registered patients who received a PleurX catheter cirrhosis-associated refractory ascites at our department from July 2015 to November 2016. Our control group consisted of matched cirrhotic patients with refractory ascites treated with large volume paracentesis (LVP) and patients with malignant ascites treated with PleurX during the same period.

RESULTS: We included 25 patients with cirrhosis-related ascites (7 in PleurX group) and 17 with malignant ascites (14 in PleurX group). Of these, six patients had hepatocellular carcinoma and cirrhosis (5 in PleurX group). None were eligible for insertion of a TIPS or liver transplantation. The maximum duration of follow-up was (480 days) in the PleurX group and 366 days in the LVP group (median 84 and 173 days, respectively). There was no difference in mortality when comparing PleurX with LVP treatment (hazard ratios: 3.0 and 1.0, p = .23 and .96, respectively). Mortality was higher in patients with malignant ascites (p= .01). We found no significant differences in adverse events (incl. spontaneous bacterial peritonitis) or in P-albumin, P-creatinine and P-sodium between the groups.

CONCLUSION: PleurX insertion for the treatment of refractory ascites in cirrhotic patients appears to be safe. Prospective randomized trials are necessary in order to confirm these findings.

OriginalsprogEngelsk
TidsskriftScandinavian Journal of Gastroenterology
Vol/bind53
Udgave nummer3
Sider (fra-til)340-344
ISSN0036-5521
DOI
StatusUdgivet - mar. 2018

ID: 52668506